The main objective of endometrial cancer surgery is complete tumor extirpation alongside accurate histopathologic staging. According to the National Comprehensive Cancer Network (NCCN Guidelines, Version 1.2024), surgery serves as both the definitive diagnostic staging mechanism and the primary therapeutic strategy for early-stage uterine cancers.

Surgical Goals and Mechanisms

The intervention removes the primary site of origin, evaluates potential microscopic spread to regional lymphatic channels, and identifies high-risk features such as deep myometrial invasion (growth into the uterine muscle layer) or lymphovascular space invasion. By classifying the cancer under the updated International Federation of Gynecology and Obstetrics (FIGO 2023) staging system, the surgical oncology team determines whether a patient requires observation alone or adjuvant treatment such as radiotherapy or systemic chemotherapy.

1. Patient Position and Anesthesia: The patient is placed in the low lithotomy position under general anesthesia. Antibiotic prophylaxis and pneumatic compression devices are administered.
2. Diagnostic Laparoscopy / Access: Peritoneal access is achieved via a umbilical port or Veress needle technique. Additional subumbilical and lower quadrant ports are inserted under direct visual guidance.
3. Peritoneal Assessment: The upper abdomen, liver, omentum, diaphragmatic surfaces, and peritoneal membranes are systematically inspected for gross metastatic disease.
4. Sentinel Lymph Node (SLN) Mapping: Indocyanine green (ICG) dye is injected into the cervical stroma at 3 and 9 o'clock positions. Near-infrared fluorescence imaging visualizes lymphatic channels leading to the primary draining sentinel nodes in the bilateral obturator and external iliac regions.
5. Sentinel Node Excision: Highlighted sentinel lymph nodes are carefully dissected and removed for ultrastaging evaluation by pathology.
6. Retroperitoneal Dissection & Ureteral Identification: The retroperitoneum is opened, and both ureters are identified and traced to ensure safety during vascular ligation.
7. Salpingo-Oophorectomy: The infundibulopelvic ligaments containing the ovarian vessels are skeletonized, retroperitoneal structures verified, and the vessels clipped and transected bilaterally.
8. Uterine Artery Ligation & Hysterectomy: The broad ligaments are divided, the uterine arteries and veins are ligated at the internal os level, and the circumvallate incision is made around the vaginal vault to free the uterus and cervix.
9. Specimen Extraction: The uterus, cervix, fallopian tubes, and ovaries are extracted intact through the vagina using an endobag to prevent tumor cell spillage.
10. Vaginal Cuff Closure: The vaginal cuff is closed using continuous or interrupted delayed-absorbable sutures.
11. Final Hemostasis and Port Closure: The surgical field is irrigated, meticulous hemostasis is confirmed, and port sites/abdominal incisions are closed layer by layer.

Surgical intervention for endometrial cancer offers well-established therapeutic and diagnostic outcomes based on extensive clinical registry data:

• High Curative Potential: For localized Stage I endometrioid carcinoma, primary surgical resection alone yields 5-year overall survival rates exceeding 90% (NCCN Guidelines 2024).
• Definitive Pathologic Staging: Provides exact micro-anatomical assessment of tumor depth, nodal status, and cervical involvement, preventing under-treatment or unnecessary exposure to radiation and chemotherapy.
• Resolution of Uterine Bleeding: Excision of the affected uterus immediately halts pathological postmenopausal bleeding or heavy abnormal menstruation.
• Integration of Sentinel Lymph Node Mapping: Replaces full systematic pelvic lymphadenectomy in early-stage disease, reducing lower extremity lymphedema (chronic tissue swelling due to lymphatic fluid accumulation) from 15–20% down to under 5% (Rossi et al., FIRES Trial, Lancet Oncology, 2017).

Recovery varies based on the surgical approach (minimally invasive vs. open laparotomy) and patient comorbidities.

Short-Term Recovery (Weeks 1–2)

During the first two weeks, patients focus on mobility and incisional healing. Light activity like walking inside the home is encouraged to prevent deep vein thrombosis. Fatigue is common. Pain management transitions from prescription analgesics to non-opioid medications like acetaminophen or ibuprofen.

Intermediate Recovery (Weeks 3–6)

Incisional healing progresses. Light non-strenuous daily activities are resumed. Patients should avoid lifting items heavier than 10 pounds (4.5 kg) and avoid vaginal penetration (no tampons, douching, or sexual intercourse) to allow the vaginal cuff (the surgical closure at the top of the vagina where the cervix was removed) to heal completely.

Long-Term Recovery (Weeks 6–12 and Beyond)

By 6 to 8 weeks, patients who underwent minimally invasive surgery are typically cleared for full activity, including exercise, driving, and sexual intercourse, following a normal physical exam. Recovery from an open abdominal incision may require 8 to 12 weeks before unrestricted heavy physical activity is safe.

Endometrial cancer surgery is indicated for the primary management and staging of several specific epithelial uterine neoplasms and premalignant conditions, including:

• Endometrioid Adenocarcinoma: The most prevalent histologic type, accounting for approximately 75% to 80% of all uterine body malignancies.
• Uterine Serous Carcinoma: An aggressive, high-grade non-endometrioid subtype that carries a higher propensity for early extrauterine spread.
• Clear Cell Adenocarcinoma: A rare, high-grade malignant subtype categorized alongside serous neoplasms as high-risk histology.
• Carcinosarcoma (Malignant Mixed Müllerian Tumor): A high-grade biphasic neoplasm composed of both epithelial and mesenchymal malignant components.
• Undifferentiated and Dedifferentiated Carcinomas: High-grade malignant variants requiring surgical removal and staging.
• Atypical Endometrial Hyperplasia / Endometrial Intraepithelial Neoplasia (EIN): Premalignant tissue changes with a high concurrent risk (up to 40%) of underlying invasive carcinoma (Trimble et al., Gynecologic Oncology, 2012).

1. Medical Optimization: Evaluation of cardiovascular, pulmonary, and renal function. Glycemic control is optimized in diabetic patients to minimize wound infection risks.
2. Imaging and Pathology Verification: Review of initial diagnostic endometrial biopsy or curettage slides by a subspecialized gynecologic pathologist. Pelvic MRI or contrast CT scans are performed if advanced stage or high-grade histology is suspected.
3. Pre-Operative Nutrition & Fasting: Strict adherence to fasting protocols (solid food stopped 6-8 hours prior; clear liquids permitted up to 2 hours prior under ERAS guidelines).
4. Thromboembolism Prophylaxis: Administration of low-molecular-weight heparin or unfractionated heparin prior to induction based on risk scoring (Caprini score).
5. Bowel Preparation: Routine mechanical bowel preparation is generally avoided per modern ERAS recommendations unless intestinal resection is anticipated.

Complications stratified by frequency and severity:

1. Common/Mild Risks:
- Minor incisional infection or wound dehiscence (3-5%)
- Postoperative urinary tract infection (2-4%)
- Transient voiding dysfunction or urinary retention (3-5%)
- Mild vaginal bleeding or spotting for 1-3 weeks

2. Moderate Risks:
- Pelvic hematoma or seroma formation (1-3%)
- Lower extremity deep vein thrombosis (DVT) or pulmonary embolism (1-2%)
- Vaginal cuff separation or delayed cuff dehiscence (0.5-1.5%)

3. Rare/Severe Complications:
- Lower extremity lymphedema (<5% with SLN mapping; 15-20% with full lymphadenectomy)
- Intraoperative injury to adjacent structures: ureteral injury (0.2-0.5%), bladder injury (0.5-1%), bowel injury (0.3-0.8%)
- Major retroperitoneal vascular hemorrhage requiring emergency transfusion or open convert (0.5%)
- Surgical mortality (<0.1% in elective cases)

Pre-Procedure Clinical Workup

Patients undergo a mandatory pre-operative evaluation including systemic health assessment, pelvic imaging (ultrasound or contrast-enhanced magnetic resonance imaging), chest radiography or computed tomography (CT), and baseline blood panels. Pre-operative anesthesia clearance and enhanced recovery protocols are established.

Intraoperative Management

In the operating room, general anesthesia is administered. The surgical team executes a total hysterectomy and bilateral salpingo-oophorectomy via minimally invasive techniques (laparoscopic or robotic-assisted) or open laparotomy. Sentinel lymph node mapping using indocyanine green dye is routinely integrated to sample pelvic nodes.

Postoperative and Early Recovery

In the immediate recovery phase, pain control, early ambulation within 6 to 12 hours, and rapid resumption of oral intake are prioritized under Enhanced Recovery After Surgery (ERAS) protocols. Most minimally invasive patients are discharged within 24 to 48 hours.

Oncologic Surveillance and Long-Term Care

Final pathology results arrive within 7 to 14 days, defining the FIGO stage and molecular risk group. Patients meet with their gynecologic oncologist to review the need for adjuvant therapy and set up a multi-year surveillance schedule including pelvic examinations every 3 to 6 months.